Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

The Trump administration’s sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US ...

Limit exposure to your employer's stock, sell it periodically and maintain portfolio diversification to protect your wealth ...

Meghan Trainor reacted after fans said she looked unrecognizable in a recent video of herself doing the Nicki Minaj stiletto challenge with a new sleek long blonde ponytail and bangs.

In its 2025 M&A trends survey, Deloitte found a sense of optimism among respondents, who cited strong performance and ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...

Renaissance Technologies’ Q2 2025 13F portfolio grew to $75B. Check out the significant stake increases and major reductions ...

Days after it was announced that the cost of Mounjaro weight-loss jabs in the UK would treble in September, sales of Ozempic had surged by 600 per cent.